MYC and diffuse large B-cell lymphoma: Thus, dysregulated ROCK2 activity can promote lymphomagenesis in ABC-DLBCL via effects on both IRF4 and MYC and inhibiting this kinase could represent a novel therapeutic approach for the treatment of ABC-DLBCL.